Naftali Kaminski, MD


Internal Medicine, Pulmonary Disease Medicine

Conditions & Treatments

Pulmonary Fibroids, Pulmonary Fibrosis


Naftali Kaminski, MD, chief of Yale Medicine Pulmonary, Critical Care and Sleep Medicine, is a leader in improving the understanding and treatment of chronic lung diseases. He has a particular interest in idiopathic pulmonary fibrosis, a disease characterized by progressive scarring of the lungs, and in chronic obstructive pulmonary disease and asthma. 

Dr. Kaminski leads the Kaminski Lab at Yale School of Medicine, where researchers apply cutting-edge technologies that measure changes in the sequence, expression or regulation of all the genes in the human genome in efforts to learn more about the roles of genome networks and biomarkers in chronic lung disease.

“Pulmonary fibrosis was an understudied and poorly understood disease, with high mortality and morbidity,” says Dr. Kaminiski, who is a professor of medicine (pulmonary) at Yale School of Medicine “I thought that by shifting the focus to human
relevant pathways and mechanisms we can have an impact, and we have.”





Affiliated With

Yale Medicine


Education & Training


Hadassah Medical School, The Hebrew University


Chaim Sheba Medical Center;UCLA Medical Center

Accepted Insurance

Insurance coverage regularly changes, please contact the doctor’s office directly to verify that your specific insurance plan is accepted.

  • aetna
  • anthem bc/bs
  • berkeley care network
  • cigna healthcare
  • community care network
  • connecticare
  • corvel
  • first health network
  • focus healthcare
  • great west
  • husky
  • medicaid
  • medicare
  • multiplan
  • oxford health plans
  • railroad medicare
  • tricare/champus
  • united healthcare
  • us family health plan
  • wellcare